4FUL
PI3 Kinase Gamma bound to a pyrmidine inhibitor
4FUL の概要
| エントリーDOI | 10.2210/pdb4ful/pdb |
| 分子名称 | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, 4-({4-[3-(piperidin-1-ylcarbonyl)phenyl]pyrimidin-2-yl}amino)benzenesulfonamide (3 entities in total) |
| 機能のキーワード | kinase, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
| 由来する生物種 | Homo sapiens (human) |
| 細胞内の位置 | Cytoplasm: P48736 |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 111193.68 |
| 構造登録者 | Gopalsamy, A.,Bennett, E.M.,Shi, M.,Zhang, W.G.,Bard, J.,Yu, K. (登録日: 2012-06-28, 公開日: 2012-10-17, 最終更新日: 2024-11-27) |
| 主引用文献 | Gopalsamy, A.,Bennett, E.M.,Shi, M.,Zhang, W.G.,Bard, J.,Yu, K. Identification of pyrimidine derivatives as hSMG-1 inhibitors. Bioorg.Med.Chem.Lett., 22:6636-6641, 2012 Cited by PubMed Abstract: hSMG-1 kinase plays a dual role in a highly conserved RNA surveillance pathway termed nonsense-mediated RNA decay (NMD) and in cellular genotoxic stress response. Since deregulation of cellular responses to stress contributes to tumor growth and resistance to chemotherapy, hSMG-1 is a potential target for cancer treatment. From our screening efforts, we have identified pyrimidine derivatives as hSMG-1 kinase inhibitors. We report structure-based optimization of this pan-kinase scaffold to improve its biochemical profile and overall kinome selectivity, including mTOR and CDK, to generate the first reported selective hSMG-1 tool compound. PubMed: 23021994DOI: 10.1016/j.bmcl.2012.08.107 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.47 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






